EAM
LGND icon

Eagle Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History

Eagle Asset Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-176,643
Closed -$11.5M – 641
2019
Q4 		$11.5M Sell
176,643
-362,861
-67% -$24.2M 0.06% 291
2019
Q3 		$33.5M Buy
539,504
+15,892
+3% +$998K 0.17% 188
2019
Q2 		$37.3M Sell
523,612
-939
-0.2% -$69.2K 0.19% 190
2019
Q1 		$41.1M Sell
524,551
-186,020
-26% -$14.1M 0.22% 176
2018
Q4 		$60.2M Buy
710,571
+64,964
+10% +$6.93M 0.38% 94
2018
Q3 		$111M Sell
645,607
-31,253
-5% -$4.71M 0.53% 41
2018
Q2 		$87.5M Sell
676,860
-22,090
-3% -$2.46M 0.47% 65
2018
Q1 		$72M Sell
698,950
-30,005
-4% -$2.97M 0.39% 85
2017
Q4 		$62.5M Sell
728,955
-55,415
-7% -$4.8M 0.34% 99
2017
Q3 		$66.6M Sell
784,370
-2,448
-0.3% -$194K 0.38% 78
2017
Q2 		$59.6M Buy
786,818
+56,568
+8% +$3.96M 0.36% 89
2017
Q1 		$48.2M Sell
730,250
-2,092
-0.3% -$138K 0.3% 100
2016
Q4 		$46.4M Buy
732,342
+461,990
+171% +$29.2M 0.31% 103
2016
Q3 		$17.2M Buy
270,352
+39,611
+17% +$2.91M 0.12% 237
2016
Q2 		$17.2M Sell
230,741
-26,824
-10% -$1.99M 0.12% 237
2016
Q1 		$17.2M Buy
257,565
+2,205
+0.9% +$134K 0.12% 244
2015
Q4 		$17.3M Buy
255,360
+52,516
+26% +$3.24M 0.12% 239
2015
Q3 		$10.8M Buy
202,844
+1,547
+0.8% +$93.9K 0.07% 321
2015
Q2 		$12.7M Buy
201,297
+26,774
+15% +$1.46M 0.07% 307
2015
Q1 		$8.39M Sell
174,523
-1,985
-1% -$76.1K 0.05% 354
2014
Q4 		$5.86M Sell
176,508
-5,251
-3% -$171K 0.03% 396
2014
Q3 		$5.33M Sell
181,759
-16,542
-8% -$549K 0.03% 424
2014
Q2 		$7.71M Buy
198,301
+4,053
+2% +$164K 0.04% 378
2014
Q1 		$8.15M Buy
194,248
+1,797
+0.9% +$74.9K 0.04% 386
2013
Q4 		$6.31M Sell
192,451
-88,137
-31% -$2.87M 0.04% 388
2013
Q3 		$7.45M Buy
+280,588
New +$7.89M 0.04% 419

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Eagle Asset Management's LGND Position: Q1 2020 in Review

Eagle Asset Management sold out of Ligand Pharmaceuticals (LGND) in Q1 2020, closing a stake of 176,643 shares — an estimated $11.5M sold.

Eagle Asset Management first reported a position in LGND in Q3 2013 and held it in 26 quarters. The position peaked at $111M in Q3 2018. 262 funds tracked by Wall St. Rank hold LGND as of Q1 2020.

  • Eagle Asset Management reported no remaining Ligand Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Eagle Asset Management sold 176,643 Ligand Pharmaceuticals shares in Q1 2020, an estimated $11.5M.
  • Eagle Asset Management first reported a position in Ligand Pharmaceuticals in Q3 2013 and held it in 26 quarters.
  • Eagle Asset Management's Ligand Pharmaceuticals position peaked at $111M in Q3 2018.
  • 262 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2020.

Based on Eagle Asset Management's 13F filing for Q1 2020, filed 11 May 2020.